Enter a player name to begin or load your saved progress.
Novavax, Inc. is an American biotechnology company headquartered in Gaithersburg, Maryland, focusing on developing vaccines for serious infectious diseases.
Answer: True
Explanation: Novavax, Inc. is indeed an American biotechnology firm based in Gaithersburg, Maryland, with a primary mission centered on the development of vaccines targeting severe infectious diseases.
Novavax was founded in 1987 and its global headquarters are located in Gaithersburg, Maryland.
Answer: True
Explanation: The company Novavax, Inc. was established in 1987 and maintains its global headquarters in Gaithersburg, Maryland, which also houses its Vaccines Innovation Campus.
Novavax's stock is traded on the New York Stock Exchange (NYSE) under the ticker symbol NVX.
Answer: False
Explanation: The source indicates that Novavax's stock is traded on the Nasdaq stock exchange under the ticker symbol NVAX, not the New York Stock Exchange under NVX.
On which stock exchange is Novavax traded, and what is its ticker symbol?
Answer: NASDAQ: NVAX
Explanation: Novavax, Inc. is a publicly traded entity whose shares are listed on the Nasdaq stock exchange, identified by the ticker symbol NVAX.
What is the primary focus of Novavax, Inc.?
Answer: Developing vaccines designed to combat serious infectious diseases.
Explanation: Novavax, Inc. is primarily focused on the development of vaccines engineered to address serious infectious diseases.
What does the term 'public company' signify for Novavax?
Answer: Its shares are available for purchase by the general public on a stock exchange.
Explanation: Being a 'public company' indicates that Novavax's shares are traded on a stock exchange, making them accessible for purchase by the general public.
Prior to 2020, Novavax's vaccine development efforts focused exclusively on cancer therapies.
Answer: False
Explanation: Before 2020, Novavax's primary vaccine development efforts were directed towards influenza and respiratory syncytial virus (RSV), alongside other emerging infectious diseases, not exclusively cancer therapies.
Novavax's ResVax vaccine candidate was designed to protect against influenza virus infection.
Answer: False
Explanation: The ResVax vaccine candidate developed by Novavax was designed to stimulate resistance against Respiratory Syncytial Virus (RSV) infection, not influenza.
NanoFlu, Novavax's influenza vaccine, received FDA fast track designation in January 2020 to proceed to Phase III trials.
Answer: True
Explanation: NanoFlu, Novavax's quadrivalent influenza vaccine, did receive FDA fast track designation in January 2020, facilitating its progression to Phase III clinical trials.
What were Novavax's main vaccine development areas *prior* to 2020?
Answer: Influenza and Respiratory Syncytial Virus (RSV)
Explanation: Prior to 2020, Novavax concentrated its vaccine development efforts on influenza and Respiratory Syncytial Virus (RSV), alongside other emerging infectious diseases.
What was the primary goal of Novavax's ResVax vaccine candidate?
Answer: To stimulate resistance to RSV infection.
Explanation: The ResVax vaccine candidate was developed by Novavax with the primary objective of stimulating resistance to Respiratory Syncytial Virus (RSV) infection, particularly through maternal immunization.
What significant challenge did Novavax face with the ResVax vaccine trials in 2019?
Answer: Late-stage clinical testing failed for a second time.
Explanation: In 2019, Novavax encountered a significant challenge when the late-stage clinical testing for its ResVax vaccine candidate failed for a second time.
What designation did the U.S. FDA grant NanoFlu, Novavax's quadrivalent influenza vaccine, in January 2020?
Answer: Fast Track Designation
Explanation: In January 2020, the U.S. Food and Drug Administration (FDA) granted 'Fast Track Designation' to NanoFlu, Novavax's quadrivalent influenza vaccine, to facilitate its advancement into Phase III trials.
In 2020, Novavax shifted its primary focus to developing its NVX-CoV2373 vaccine for COVID-19.
Answer: True
Explanation: During 2020, Novavax strategically redirected its primary development efforts towards the creation and approval of its NVX-CoV2373 vaccine, specifically designed to combat COVID-19.
The brand name for Novavax's COVID-19 vaccine is NVX-CoV2373, and it is a viral vector vaccine.
Answer: False
Explanation: The development candidate designation for Novavax's COVID-19 vaccine is NVX-CoV2373, while its brand name is Nuvaxovid. Furthermore, it is classified as a protein subunit vaccine, not a viral vector vaccine.
Novavax's NVX-CoV2373 COVID-19 vaccine is a protein subunit vaccine that uses the SARS-CoV-2 spike protein and the Matrix-M adjuvant.
Answer: True
Explanation: Novavax's NVX-CoV2373 vaccine is indeed a protein subunit vaccine, incorporating the spike protein of the SARS-CoV-2 virus and utilizing the Matrix-M adjuvant to enhance immunogenicity.
Novavax's COVID-19 vaccine demonstrated 89% efficacy in Phase III trials announced in January 2021.
Answer: True
Explanation: Data from Novavax's Phase III trials, released in January 2021, indicated that its COVID-19 vaccine achieved an efficacy rate of 89%.
A US/Mexico Phase 3 trial announced in June 2021 showed Novavax's COVID-19 vaccine efficacy at 90.4%.
Answer: True
Explanation: An announcement in June 2021 regarding a Phase 3 trial conducted in the US and Mexico revealed that Novavax's COVID-19 vaccine demonstrated an overall efficacy of 90.4%.
Novavax's vaccine showed a significantly higher antibody response against the Omicron variant compared to the original strain.
Answer: False
Explanation: Contrary to the statement, Novavax announced in December 2021 that while its vaccine elicited an immune response against the Omicron variant, the antibody response was notably lower compared to the original SARS-CoV-2 strain.
What efficacy rate did Novavax's COVID-19 vaccine demonstrate in Phase III trials announced in January 2021?
Answer: 89%
Explanation: In January 2021, Novavax announced that its COVID-19 vaccine demonstrated an efficacy of 89% in its Phase III clinical trials.
How did Novavax's vaccine respond to the Omicron variant, according to announcements in December 2021?
Answer: It demonstrated an immune response, though antibody response was lower, and a third dose boosted it.
Explanation: In December 2021, Novavax reported that its vaccine generated an immune response against the Omicron variant, albeit with a reduced antibody response compared to the original strain. A subsequent third dose was shown to significantly increase neutralizing antibodies.
What is the brand name of Novavax's COVID-19 vaccine?
Answer: Nuvaxovid
Explanation: The brand name designated for Novavax's COVID-19 vaccine is Nuvaxovid, with NVX-CoV2373 serving as its development candidate designation.
What type of vaccine technology does Novavax's NVX-CoV2373 utilize?
Answer: Protein subunit
Explanation: Novavax's NVX-CoV2373 vaccine employs protein subunit technology, incorporating the SARS-CoV-2 spike protein.
The Bill and Melinda Gates Foundation provided Novavax with $89 million in 2015 for COVID-19 vaccine development.
Answer: False
Explanation: The Bill and Melinda Gates Foundation provided Novavax with $89 million in 2015, but this funding was designated to support the development of its RSV vaccine, not for COVID-19 vaccine development.
CEPI provided Novavax with $384 million in May 2020 to support its COVID-19 vaccine development.
Answer: True
Explanation: The Coalition for Epidemic Preparedness Innovations (CEPI) provided Novavax with $384 million in May 2020 to advance the development and manufacturing of its COVID-19 vaccine candidate.
Novavax received a $1.6 billion grant from the U.S. government via Operation Warp Speed in July 2020.
Answer: False
Explanation: In July 2020, Novavax received a $1.6 billion loan from the U.S. government through Operation Warp Speed, not a grant. This funding was intended for testing, commercialization, and production.
The $1.6 billion Operation Warp Speed funding aimed to produce 100 million doses of Novavax's vaccine by January 2021.
Answer: True
Explanation: The $1.6 billion funding provided by Operation Warp Speed was allocated to support the testing, commercialization, and manufacturing of Novavax's vaccine, with the goal of producing 100 million doses by January 2021.
Which organization provided Novavax with $89 million in 2015 to support RSV vaccine development?
Answer: The Bill and Melinda Gates Foundation
Explanation: In 2015, the Bill and Melinda Gates Foundation provided Novavax with $89 million to support the development of its RSV vaccine, particularly for infant protection via maternal immunization.
What was the amount and source of significant U.S. government funding Novavax received in July 2020 for COVID-19 vaccine development?
Answer: $1.6 billion loan from Operation Warp Speed
Explanation: In July 2020, Novavax secured a $1.6 billion loan from the U.S. government via the Operation Warp Speed program to aid in the testing, commercialization, and production of its COVID-19 vaccine candidate.
Takeda Pharmaceutical Company was designated to manufacture and distribute Novavax's vaccine in Japan under an agreement for 150 million doses.
Answer: True
Explanation: Takeda Pharmaceutical Company was indeed designated to manufacture and distribute Novavax's vaccine candidate in Japan, following an agreement for 150 million doses, pending regulatory approval.
Novavax reported revenue of $983.7 million in 2023, which was an increase from prior years.
Answer: False
Explanation: Novavax reported revenue of US$983.7 million in 2023, which represented a decrease compared to previous financial periods, not an increase.
Novavax sold its Czech manufacturing facility to Novo Nordisk in December 2024 for $200 million.
Answer: True
Explanation: Between 2022 and 2024, Novavax divested certain assets, including the sale of its Czech manufacturing facility to Novo Nordisk in December 2024 for $200 million.
Novavax partnered with Sanofi in October 2024 for $1.2 billion, granting Sanofi rights to use the Matrix-M adjuvant.
Answer: True
Explanation: In October 2024, Novavax entered into a significant $1.2 billion partnership with Sanofi, which grants Sanofi the rights to utilize Novavax's proprietary Matrix-M adjuvant for its own product development initiatives.
What does Novavax's 2023 revenue figure of US$983.7 million indicate?
Answer: The total income generated from business activities, which was a decrease from prior periods.
Explanation: Novavax's reported revenue of US$983.7 million in 2023 signifies the total income from its business operations, reflecting a decline compared to earlier financial periods.
What strategic operational change did Novavax make between 2022 and 2024?
Answer: Sold its Czech manufacturing facility.
Explanation: Between 2022 and 2024, Novavax implemented strategic operational changes, including the sale of its Czech manufacturing facility in December 2024.
What is the purpose of the partnership between Novavax and Sanofi announced in October 2024?
Answer: Sanofi gains rights to use Novavax's Matrix-M adjuvant for its own product development.
Explanation: The partnership between Novavax and Sanofi, established in October 2024, allows Sanofi to leverage Novavax's Matrix-M adjuvant for the development of its own products.
Novavax acquired its Matrix-M adjuvant platform in June 2013 from a Swedish company named Isconova AB.
Answer: True
Explanation: Novavax acquired the Matrix-M adjuvant platform, originally developed by Isconova AB, in June 2013, subsequently integrating it into its vaccine development pipeline.
When did Novavax acquire the Matrix-M adjuvant platform?
Answer: June 2013
Explanation: Novavax completed the acquisition of the Matrix-M adjuvant platform in June 2013.
Phase III clinical trials are conducted on small groups to determine initial safety.
Answer: False
Explanation: Phase III clinical trials involve a very large group of participants to confirm efficacy and monitor side effects, rather than determining initial safety, which is the primary goal of Phase I trials.
What is the function of an adjuvant in a vaccine?
Answer: To stimulate a stronger immune response.
Explanation: An adjuvant is an ingredient added to a vaccine formulation specifically to enhance the recipient's immune response, thereby increasing the vaccine's overall effectiveness.
What does 'fast track designation' from the FDA imply for a vaccine candidate?
Answer: Expedited review and development for serious conditions.
Explanation: A 'fast track designation' granted by the FDA signifies an expedited pathway for the review and development of medical products intended for serious conditions that address unmet medical needs.
What is the significance of Novavax's proprietary vaccine adjuvants?
Answer: They are immune-stimulating saponin-based platforms that enhance vaccine immunogenicity.
Explanation: Novavax's proprietary vaccine adjuvants, such as Matrix-M, are significant as they are immune-stimulating saponin-based platforms designed to enhance the immunogenicity of vaccines.